NorthStrive Biosciences amends License Agreement with MOA Life Plus, updating timelines for clinical development of EL-32 and EL-22.
Quiver AI Summary
PMGC Holdings Inc. announced a third amendment to the License Agreement held by its subsidiary, NorthStrive Biosciences Inc., with Korean biotechnology company MOA Life Plus Co., Ltd. This amendment focuses on updating the development milestones and timing for the human clinical programs of EL-32 and EL-22, ensuring alignment with research and regulatory expectations. NorthStrive sees this move as a reinforcement of its commitment to methodical development in its human health portfolio. EL-22 aims to address obesity by preserving muscle in patients undergoing weight loss treatments. PMGC Holdings continues to diversify through strategic acquisitions and investments across various sectors.
Potential Positives
- NorthStrive Biosciences announced a third amendment to its License Agreement with MOA Life Plus Co., Ltd., which may facilitate the advancement of its human clinical development programs for EL-32 and EL-22.
- The Amendment reinforces the company's commitment to disciplined development planning and supports the continued progression of its human health portfolio, indicating potential for future advancements in biopharmaceuticals.
- Alignment of the development timeline with the parties’ research and regulatory expectations suggests improved collaboration and strategic planning between NorthStrive and MOA Life, which could enhance project success rates.
Potential Negatives
- The press release emphasizes a reliance on forward-looking statements, which may create uncertainty around the company's future performance and development timelines, potentially leading to investor skepticism.
- The need for a third amendment to the License Agreement may indicate previous delays or issues in the development timeline for EL-32 and EL-22, raising concerns about project management and execution.
- NorthStrive Biosciences’ positioning in an emerging market could expose PMGC to significant competition and regulatory hurdles, which are not explicitly addressed in the release.
FAQ
What is the recent amendment to PMGC's License Agreement?
The amendment updates the timing and milestones for EL-32 and EL-22 human clinical development programs.
How does this amendment benefit NorthStrive Biosciences?
The amendment reinforces the company's commitment to disciplined development planning for its human health portfolio.
What are EL-32 and EL-22?
EL-32 and EL-22 are assets in NorthStrive Biosciences' human clinical development programs focused on biopharmaceutical innovations.
What is MOA Life Plus Co., Ltd.?
MOA Life Plus Co., Ltd. is a Korean biotechnology firm specializing in innovative therapeutic technologies for health applications.
Where can I find more information about PMGC Holdings Inc.?
More information can be found on PMGC Holdings Inc.'s official website at https://www.pmgcholdings.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ELAB Hedge Fund Activity
We have seen 2 institutional investors add shares of $ELAB stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SABBY MANAGEMENT, LLC removed 5,307 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $28,074
- TOWER RESEARCH CAPITAL LLC (TRC) added 3,133 shares (+inf%) to their portfolio in Q4 2025, for an estimated $18,547
- CITADEL ADVISORS LLC removed 1,273 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $26,936
- UBS GROUP AG added 308 shares (+263.2%) to their portfolio in Q4 2025, for an estimated $455
- CITIGROUP INC removed 184 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $272
- BANK OF AMERICA CORP /DE/ removed 2 shares (-50.0%) from their portfolio in Q4 2025, for an estimated $2
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEWPORT BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.’s (NASDAQ: ELAB) (“PMGC,” “we,” or “our”) wholly owned subsidiary, NorthStrive Biosciences Inc. (“Northstrive Biosciences”), announced today a third amendment (“Amendment”) to its existing License Agreement with MOA Life Plus Co., Ltd., [KOSDAQ: 142760] a Korean biotechnology company (“MOA,” and such existing agreement, as amended, “License Agreement”) Northstrive Biosciences holds for EL-32 and EL-22.
The Amendment updates the timing and key development milestones for EL-32 and EL-22 human clinical development programs, aligning the schedule with the parties’ research and development and regulatory expectations.
Northstrive Biosciences believes the Amendment reinforces the company’s commitment to disciplined development planning and the continued progression of its human health portfolio.
About MOA Life Plus Co. Ltd. [KOSDAQ: 142760]
MOA Life Plus Co. Ltd.is a Korean biotechnology company focused on the research, development, and commercialization of innovative therapeutic and wellness technologies. MOA partners globally to advance scientific innovation across human and animal health applications.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
